Translating scientific discoveries into
affordable, accessible public health solutions


What We Do


new approaches to developing vaccines and other means of preventing HIV.


translational and clinical research through our laboratories in the U.S., India, and the U.K.

Build Capacity

in-country for researching vaccine candidates while strengthening local public health and scientific expertise.


with industry and enlist biopharma product development skills to develop innovative products tailored to target populations.


IAVI’s resources with other innovators to help the HIV community as a whole succeed.


IAVI’s core capabilities to solving disease prevention and treatment challenges.

Latest News from IAVI

Vaccine being given in arm

Phase I Trial of Native-like HIV Env Trimer

Phase I Trial to Evaluate Safety and Immunogenicity of Engineered Envelope Protein

Scientist in Lab

Need for TB Vaccine Research Support

World TB Day falls on March 24 each year. It marks the day in 1882 when Robert Koch announced that he had identified the cause of TB.

IAVI-Led Study Explores Gene Transfer for HIV Antibody Expression

First-in-human clinical trial results of IAVI A003 study published in The Lancet HIV

IAVI Report: Antibodies & Optimism

Scientists are more optimistic than ever about developing HIV vaccines and antibody-based products.

Donor Spotlight: Netherlands Ministry of Foreign Affairs

IAVI recognizes the Ministry of Foreign Affairs of the Netherlands for its continued support for the development of HIV vaccines and other prevention tools.

The Need for Long-Acting HIV Prevention

Women living in Kenya and South Africa describe the cultural and economic barriers to HIV prevention.



Kenya HIV & AIDS Research Agenda